Divi's Laboratories Overview

  • Year Founded
  • 1990

Year Founded

  • Status
  • Public

  • Employees
  • 16,911

Employees

  • Stock Symbol
  • DIVISLAB

Stock Symbol

  • Share Price
  • $54.99
  • (As of Thursday Closing)

Divi's Laboratories General Information

Description

Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. Most of the company's sales are generated in Europe, followed by North America, India, and Asia. The company has three distinct business segments: Generic APIs, Custom Synthesis, and Nutraceuticals. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
NSE
Corporate Office
  • Divi Towers, Cyber Hills
  • Gachibowli
  • Hyderabad, 500032
  • India
+91 040 0000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Divi's Laboratories Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$54.99 $53.26 $39.63 - $55.27 $14.6B 265M 626K $0.73

Divi's Laboratories Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2024 31-Mar-2024 FY 2023 31-Mar-2023 FY 2022 31-Mar-2022
EV 10,533,535 10,533,535 8,719,505 15,157,748
Revenue 947,626 947,626 967,274 1,180,985
EBITDA 307,299 307,299 337,867 526,983
Net Income 193,270 193,270 227,154 397,336
Total Assets 1,855,061 1,855,061 1,758,660 1,763,815
Total Debt 360 360 397 487
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Divi's Laboratories Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Divi's Laboratories‘s full profile, request access.

Request a free trial

Divi's Laboratories Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. Most of the company's sales are generated
Drug Discovery
Hyderabad, India
16,911 As of 2023
00.000
000000000 00.000

00000

Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliqu
000000000000000
Ahmedabad, India
00000 As of 0000
000.00
0000 000.00

00000

n reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
000000000000000
Ahmedabad, India
00000 As of 0000
000.00
00.00 0000-00-00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Divi's Laboratories Competitors (7)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Zydus Lifesciences Corporation Ahmedabad, India 00000 000.00 0000 000.00
Intas Pharmaceuticals Private Equity-Backed Ahmedabad, India 00000 000.00 00000000000 000.00
Glenmark Pharmaceuticals Corporation Mumbai, India 00000 00000 00000000000 00000
WuXi AppTec Formerly PE-Backed Shanghai, China 00000 00.000 000000000 00.000
Evotec Formerly PE-Backed Hamburg, Germany 0000 00000 000000000 00000
You’re viewing 5 of 7 competitors. Get the full list »

Divi's Laboratories Patents

Divi's Laboratories Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230373914-A1 Process for the preparation of (r)-4-propyl pyrrolidine-2-one, a key intermediate for synthesis of brivaracetam Active 23-May-2022 0000000000
JP-2023172821-A Improved process for preparation of (r)-4-propyl pyrrolidine-2-one, key intermediate for synthesis of brivaracetam Active 23-May-2022 00000000 0
EP-4282971-A1 An improved process for the preparation of (r )-4-propyl pyrrolidine-2-one, a key intermediate for synthesis of brivaracetam Pending 23-May-2022 00000000 0
JP-7402935-B2 An improved process for the preparation of (r)-4-propylpyrrolidin-2-one, a key intermediate for the synthesis of brivaracetam. Active 23-May-2022 00000000 0
US-11884623-B2 Process for the preparation of (r)-4-propyl pyrrolidine-2-one, a key intermediate for synthesis of brivaracetam Active 23-May-2022 C07D207/27 00
To view Divi's Laboratories’s complete patent history, request access »

Divi's Laboratories Executive Team (4)

Name Title Board Seat Contact Info
Satchandra Divi Chief Executive Officer & Board Member
Madhusudana Divi Board Member & Executive
Nilima Divi Board Member & Executive
Murali Divi Ph.D Board Member & Founder
To view Divi's Laboratories’s complete executive team members history, request access »

Divi's Laboratories Board Members (9)

Name Representing Role Since
00000000 0000 Divi's Laboratories Board Member 000 0000
0000000 0000000000 Divi's Laboratories Board Member 000 0000
00000000000 0000 Divi's Laboratories Board Member & Executive 000 0000
000000 0000 00.0 Divi's Laboratories Board Member & Founder 000 0000
000000 0000 Divi's Laboratories Board Member & Executive 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Divi's Laboratories Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Divi's Laboratories Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Divi's Laboratories‘s full profile, request access.

Request a free trial

Divi's Laboratories ESG

Risk Overview

Risk Rating

Updated May, 31, 2024

32.79 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,191

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 921

Rank

00.00

Percentile

Pharmaceuticals

Subindustry

00 of 452

Rank

00.00

Percentile

To view Divi's Laboratories’s complete esg history, request access »

Divi's Laboratories FAQs

  • When was Divi's Laboratories founded?

    Divi's Laboratories was founded in 1990.

  • Who is the founder of Divi's Laboratories?

    Murali Divi Ph.D is the founder of Divi's Laboratories.

  • Who is the CEO of Divi's Laboratories?

    Satchandra Divi is the CEO of Divi's Laboratories.

  • Where is Divi's Laboratories headquartered?

    Divi's Laboratories is headquartered in Hyderabad, India.

  • What is the size of Divi's Laboratories?

    Divi's Laboratories has 16,911 total employees.

  • What industry is Divi's Laboratories in?

    Divi's Laboratories’s primary industry is Drug Discovery.

  • Is Divi's Laboratories a private or public company?

    Divi's Laboratories is a Public company.

  • What is Divi's Laboratories’s stock symbol?

    The ticker symbol for Divi's Laboratories is DIVISLAB.

  • What is the current stock price of Divi's Laboratories?

    As of 13-Jun-2024 the stock price of Divi's Laboratories is $54.99.

  • What is the current market cap of Divi's Laboratories?

    The current market capitalization of Divi's Laboratories is $14.6B.

  • What is Divi's Laboratories’s current revenue?

    The trailing twelve month revenue for Divi's Laboratories is $948M.

  • Who are Divi's Laboratories’s competitors?

    Zydus Lifesciences, Intas Pharmaceuticals, Glenmark Pharmaceuticals, WuXi AppTec, and Evotec are some of the 7 competitors of Divi's Laboratories.

  • What is Divi's Laboratories’s annual earnings per share (EPS)?

    Divi's Laboratories’s EPS for 12 months was $0.73.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »